DB:8AT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Aclaris Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8AT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.4%

8AT

0.2%

DE Pharmaceuticals

7.9%

DE Market


1 Year Return

-68.9%

8AT

16.4%

DE Pharmaceuticals

6.3%

DE Market

Return vs Industry: 8AT underperformed the German Pharmaceuticals industry which returned 16.4% over the past year.

Return vs Market: 8AT underperformed the German Market which returned 6.3% over the past year.


Shareholder returns

8ATIndustryMarket
7 Day3.4%0.2%7.9%
30 Day-3.2%-0.2%12.8%
90 Day33.3%8.7%15.6%
1 Year-68.9%-68.9%20.2%16.4%8.1%6.3%
3 Year-94.5%-94.5%26.4%11.8%1.0%-6.7%
5 Yearn/a31.3%8.6%13.9%-0.8%

Price Volatility Vs. Market

How volatile is Aclaris Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aclaris Therapeutics undervalued compared to its fair value and its price relative to the market?

1.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8AT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8AT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8AT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 8AT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8AT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8AT is good value based on its PB Ratio (1x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Aclaris Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

4.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8AT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8AT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8AT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8AT's revenue (26.2% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: 8AT's revenue (26.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8AT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aclaris Therapeutics performed over the past 5 years?

-37.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8AT is currently unprofitable.

Growing Profit Margin: 8AT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8AT is unprofitable, and losses have increased over the past 5 years at a rate of -37.4% per year.

Accelerating Growth: Unable to compare 8AT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8AT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).


Return on Equity

High ROE: 8AT has a negative Return on Equity (-174.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aclaris Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 8AT's short term assets ($82.7M) exceed its short term liabilities ($20.6M).

Long Term Liabilities: 8AT's short term assets ($82.7M) exceed its long term liabilities ($18.0M).


Debt to Equity History and Analysis

Debt Level: 8AT's debt to equity ratio (18.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 8AT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8AT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 8AT has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 37.5% each year.


Next Steps

Dividend

What is Aclaris Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8AT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8AT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8AT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8AT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8AT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Neal Walker (49yo)

7.92yrs

Tenure

US$3,150,021

Compensation

Dr. Neal S. Walker, D.O., Co-founded Aclaris Therapeutics, Inc. in 2012 and also has been its Chief Executive Officer and President since July 2012. Dr. Walker is also Co-Founding Member and Partner of NeX ...


CEO Compensation Analysis

Compensation vs Market: Neal's total compensation ($USD3.15M) is above average for companies of similar size in the German market ($USD427.99K).

Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder7.92yrsUS$3.15m2.6% $1.4m
Frank Ruffo
Co-Founder7.92yrsUS$1.16m0.51% $267.5k
David Gordon
Chief Medical Officer2.08yrsUS$1.37m0.20% $104.7k
Kamil Ali-Jackson
Co-Founder7.92yrsUS$2.73m0.29% $155.2k
Michael Tung
Senior VP of Corporate Strategy/Investor Relationsno datano datano data
Sheila Kennedy
Vice President of Marketingno datano datano data
Kevin Scott
Vice President of Sales4.08yrsno datano data
Jeffrey Wayne
Interim Head of Commercialno datano datano data
Joseph Monahan
Executive Vice President of Research & Developmentno datano datano data
Gary DeCrescenzo
Senior Vice President of Pharmaceutical Research & Development0.58yrno datano data

6.0yrs

Average Tenure

50yo

Average Age

Experienced Management: 8AT's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder7.92yrsUS$3.15m2.6% $1.4m
Mark Bradshaw
Member of Advisory Boardno datano datano data
James Leyden
Member of Advisory Boardno datano datano data
Klaus Theobald
Member of Advisory Boardno datano datano data
Anand Mehra
Independent Director5.75yrsUS$80.87k0.021% $11.2k
Guy Webster
Member of Advisory Boardno datano datano data
Christopher Molineaux
Independent Chairman1yrUS$88.81k0.040% $20.9k
Bryan Reasons
Independent Director2.17yrsUS$87.21k0.021% $11.2k
Kenneth Beer
Member of Advisory Boardno datano datano data
Leslie Baumann
Member of Advisory Boardno datano datano data

4.0yrs

Average Tenure

53yo

Average Age

Experienced Board: 8AT's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Aclaris Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aclaris Therapeutics, Inc.
  • Ticker: 8AT
  • Exchange: DB
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$59.869m
  • Listing Market Cap: US$52.900m
  • Shares outstanding: 41.87m
  • Website: https://www.aclaristx.com

Number of Employees


Location

  • Aclaris Therapeutics, Inc.
  • 640 Lee Road
  • Suite 200
  • Wayne
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACRSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2015
8ATDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2015
0H8TLSE (London Stock Exchange)YesCommon StockGBUSDOct 2015

Biography

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company’s products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/07 05:25
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.